A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

• ClinicalTrials.gov Identifier: NCT03548220
• Recruitment Status: Completed
• First Posted: June 7, 2018
• Results First Posted: May 24, 2022
• Last Update Posted: May 24, 2022
• Sponsor: Agios Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Agios Pharmaceuticals, Inc.

Study Description

Brief Summary:

Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.

Condition or disease	Intervention/treatment	Phase
Pyruvate Kinase Deficiency; Anemia, Hemolytic	Drug: Placebo; Drug: AG-348	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
• Actual Study Start Date: August 9, 2018
• Actual Primary Completion Date: October 9, 2020
• Actual Study Completion Date: October 9, 2020

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.	Drug: Placebo; Placebo matching AG-348 tablets, administered to maintain the blind.
Experimental: AG-348, 5 mg; Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.	Drug: AG-348; AG-348 tablets.
Experimental: AG-348, 20 mg; Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.	Drug: AG-348; AG-348 tablets.
Experimental: AG-348, 50 mg; Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.	Drug: AG-348; AG-348 tablets.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR) [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   Hemoglobin response (HR) is defined as a ≥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Secondary Outcome Measures :

1. Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24 [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
2. Maximum Change From Baseline in Hb Concentration [ Time Frame: Baseline, up to Week 24 ]
   This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
3. Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More [ Time Frame: Baseline, up to Week 24 ]
   This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
4. Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24 [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
5. Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24 [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
6. Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24 [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
7. Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24 [ Time Frame: Baseline, Weeks 16, 20, 24 ]
   The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
8. Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24 [ Time Frame: Baseline, Week 24 ]
   The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
9. Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24 [ Time Frame: Baseline, Week 24 ]
   The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
10. Percentage of Participants With Adverse Events [ Time Frame: From signing of informed consent form to the end of study, including follow-up (up to Day 197) ]
    An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
11. Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12 [ Time Frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12) ]
12. Maximum Plasma Concentration (Cmax) for AG-348 [ Time Frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12) ]
13. Time to Cmax (Tmax) for AG-348 [ Time Frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12) ]
14. Time to Last Measurable Concentration (Tlast) for AG-348 [ Time Frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12) ]
15. Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters [ Time Frame: From first dose of mitapivat to the end of study, including follow-up (up to Day 197) ]
    Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model.
16. Exposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters [ Time Frame: Baseline, Week 24 ]
    Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants.

Other Outcome Measures:

1. Percentage of Participants With Adverse Events of Special Interest (AESI) [ Time Frame: Through 4 weeks after last dose (approximately Week 31) ]
   An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.
2. Change From Baseline in Bone Mineral Density Z-Score at Week 24 [ Time Frame: Baseline, Week 24 ]
3. Change From Baseline in Bone Mineral Density T-Score at Week 24 [ Time Frame: Baseline, Week 24 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Informed consent;
• Male or female, aged 18 years or older;
• Documented clinical laboratory confirmation of pyruvate kinase (PK) deficiency, defined as documented presence of at least 2 mutant alleles in the PKLR gene, of which at least 1 is a missense mutation;
• Hemoglobin (Hb) concentration less than or equal to 10.0 grams per deciliter (g/dL) regardless of gender (average of at least 2 Hb measurements [separated by a minimum of 7 days] during the Screening Period)
• Considered not regularly transfused, defined as having had no more than 4 transfusion episodes in the 12-month period up to the first day of study treatment and no transfusions in the 3 months prior to the first day of study treatment;
• Received at least 0.8 mg oral folic acid daily for at least 21 days prior to the first dose of study treatment, to be continued daily during study participation.
• Adequate organ function;
• Women of reproductive potential, have a negative serum pregnancy test;
• For women of reproductive potential as well as men with partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study treatment for women and 90 days for men following the last dose of study treatment;
• Willing to comply with all study procedures for the duration of the study;

Exclusion Criteria:

• Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene;
• Significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data;
• Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing informed consent;
• Currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo. Prior and subsequent participation in the PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is permitted however, concurrent participation is not; participants enrolling in this current study will be expected to temporarily suspend participation in the NHS or Registry;
• Exposure to any investigational drug, device, or procedure within 3 months prior to the first dose of study treatment;
• Prior treatment with a pyruvate kinase activator;
• Prior bone marrow or stem cell transplant;
• Currently pregnant or breastfeeding;
• History of major surgery within 6 months of signing informed consent;
• Currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4, strong inducers of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or a timeframe equivalent to 5 half-lives (whichever is longer) prior to the first dose of study treatment;
• Currently receiving hematopoietic stimulating agents that have not been stopped for a duration of at least 28 days prior to the first dose of study treatment;
• History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis, or other serious clinical manifestations;
• History of allergy to AG-348 or its excipients;
• Currently receiving anabolic steroids, including testosterone preparations, within 28 days prior to treatment.

Contacts and Locations

Locations

United States, Arkansas

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States, 72205

United States, Georgia

Emory University

Atlanta, Georgia, United States, 30322

United States, Indiana

Indiana Hemophilia and Thrombosis Center

Indianapolis, Indiana, United States, 46260

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

The Children's Hospital Corporation d/b/a Boston's Children Hospital

Boston, Massachusetts, United States, 02115

United States, Michigan

Wayne State University School of Medicine, Children's Hospital of Michigan

Detroit, Michigan, United States, 48304

United States, North Carolina

Duke University

Durham, North Carolina, United States, 27705

East Carolina University

Greenville, North Carolina, United States, 27858

United States, Ohio

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

United States, Texas

Houston Methodist Research Institute

Houston, Texas, United States, 77030

United States, Utah

Primary Children's Hospital Univ. of Utah

Salt Lake City, Utah, United States, 84112

United States, Washington

Seattle Cancer Care Alliance

Seattle, Washington, United States, 98109

Brazil

Hospital Central da Faculdade de Medicina USP Cidade Universitaria

São Paulo, Brazil

Canada

McMaster University - Health Sciences Centre

Hamilton, Canada, L8S 4LB

Toronto General Hospital, University Health Network

Toronto, Canada, M5G 2C4

Czechia

Institute of Hematology and Blood Transfusion

Prague, Czechia

Denmark

University of Copenhagen, Herlev Hospital

Herlev, Denmark, 2730

France

CHU Amiens Picardie

Amiens, France, 80054

Hopital Saint-Andre

Bordeaux, France

Hôpital Henri-Mondor

Créteil, France, 94010

Hôpital de la Timone

Marseille, Cedex 5, France, 13385

Institut Claudius Regaud

Toulouse, France

Germany

Charite University Medicine

Berlin, Germany

Universitätsklinikum Würzburg

Würzburg, Germany, 97080

Italy

Ospedale Galliera

Genova, Italy, 16128

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Milano, Italy, 20122

AOU Policlinico, Università della Campania "Luigi Vanvitelli"

Napoli, Italy, 80138

Japan

Tohoku University Hospital

Sendai-City, Miyagi, Japan

Kyoto Katsura Hospital

Kyoto, Japan

Agios Investigative Site

Mie, Japan

Osaka City General Hospital

Osaka, Japan, 534-0021

Kansai Medical University, Department of Pediatrics, Hirakata Hospital

Osaka, Japan

Toho University Omori Medical Center

Tokyo, Japan

Korea, Republic of

Yeungnam University Hospital

Daegu 705-703, Korea, Republic of, 42415

Netherlands

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands, 3584

Spain

Hospital U. Vall d'Hebron Servicio de Hematología Clínica

Barcelona, Spain, 08035

Hospital Clinico Universitario Virgen de la Arricaxa

El Palmar, Spain, 30120

Hospital Universitario La Paz

Madrid, Spain, 28046

Switzerland

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Switzerland, 1011

Thailand

Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj

Bangkok, Thailand, 10700

Turkey

Hacettepe University

Ankara, Turkey

United Kingdom

Addenbrooke's Hospital

Cambridge, United Kingdom, 94609

The Royal Liverpool and Broadgreen University

Liverpool, United Kingdom, L7 8XP

Imperial College Healthcare NHS Trust, Hammersmith Hospital

London, United Kingdom, W12 0NN

University College London

London, United Kingdom, W12 0NN

Manchester Royal Infirmary

Manchester, United Kingdom, M13 9WL

Sponsors and Collaborators

Agios Pharmaceuticals, Inc.

Investigators

• Study Chair: Medical Affairs; Agios Pharmaceuticals, Inc.

  Study Documents (Full-Text)

Documents provided by Agios Pharmaceuticals, Inc.:

Study Protocol  [PDF] August 14, 2019

Statistical Analysis Plan  [PDF] June 30, 2020

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Al-Samkari H, Galacteros F, Glenthoj A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634.

Rab MAE, Van Oirschot BA, Kosinski PA, Hixon J, Johnson K, Chubukov V, Dang L, Pasterkamp G, Van Straaten S, Van Solinge WW, Van Beers EJ, Kung C, Van Wijk R. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021 Jan 1;106(1):238-249. doi: 10.3324/haematol.2019.238865.

• Responsible Party: Agios Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT03548220
• Other Study ID Numbers: AG348-C-006
• First Posted: June 7, 2018
• Results First Posted: May 24, 2022
• Last Update Posted: May 24, 2022
• Last Verified: May 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Anemia, Hemolytic, Congenital Nonspherocytic; Anemia, Hemolytic; Pyruvate Metabolism, Inborn Errors; Anemia, Hemolytic, Congenital; Anemia; Hematologic Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Mitapivat; Enzyme Activators; Molecular Mechanisms of Pharmacological Action